Bipolar Depression Update 2015
|
|
- Melanie Phillips
- 6 years ago
- Views:
Transcription
1 Bipolar Depression Update 2015 Andrew A. Nierenberg, MD Thomas P. Hackett, MD, Chair in Psychiatry Director, Bipolar Clinic and Research Program Massachusetts General Hospital Professor of Psychiatry, Harvard Medical School
2 Disclosures I have the following relevant financial relationships to disclose:
3 Andrew A. Nierenberg, MD Disclosure Statement Employee Of Consultant For Stockholder In Grant Support From Honoraria From Massachusetts General Hospital Abbott Laboratories, Astra Zeneca, Basilea, BrainCells Inc., Bristol- Myers Squibb, Cephalon, Clintara, Corcept, Eli Lilly & Co., Forest, Genaissance, Genentech, GlaxoSmithKline, Innapharma, Janssen Pharmaceutica, Jazz Pharmaceuticals, Lundbeck, Medavante, Merck, Novartis, PamLabs, PGx Health, Pfizer, Roche, Sepracor, Schering-Plough, Shire, Somerset, Sunovion, Takeda, Targacept, Teva Appliance Computing, Inc. (MindSite); Brain Cells, Inc., Medavante AFSP, AHRQ, Bristol-Myers Squibb, Cederroth, Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Eli Lilly, NARSAD, NIMH, PCORI, Pfizer, Shire, Stanley Foundation, Takeda, Wyeth-Ayerst Prior to 3 years ago, honoraria from: Bristol-Myers Squibb, Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline, Eli Lilly,, Shire, Wyeth-Ayerst, No speaker bureaus since 2003
4 Andrew A. Nierenberg, MD Disclosure Statement Other Income MBL Publishing for past services as Editor-in-chief of CNS Spectrums; Slack Inc. for services as Associate Editor of Psychiatric Annals; Editorial Board, Mind Mood Memory, Belvior Publications Patents and Copyrights Copyright joint ownership with MGH for Structured Clinical Interview for MADRS and Clinical Positive Affect Scale Additional Honoraria ADURS, Brain and Behavior Foundation Colvin Prize, University of :Pisa, University of Wisconsin at Madison, University Texas Southwest at Dallas, Health New England and Harold Grinspoon Charitable Foundation and Eli Lilly and AstraZeneca, American Society for Clinical Psychopharmacology and Zucker Hillside Hospital and Forest and Janssen, Brandeis University, International Society for Bipolar Disorder
5 Outline Bipolar depression: Basics FDA Approved Treatments Antidepressants and other treatments
6 Bipolar Depression Basics
7 Response, Remission, Recovery, Relapse, Recurrence: Phases of Treatment of Bipolar Disorder Mania Hypomania Euthymia Minor Depression Major Depression Preliminary Phase Frank E, et al. Biol Psychiatry. 2000;48(6): Preventative Phase
8 Bipolar CHOICE Baseline Symptoms: Mania Symptoms in Bipolar Depression
9 Five year outcome of bipolar I and II disorders: findings of the Jorvi Bipolar Study Bipolar Disorders Volume 17, Issue 4, pages , 2 MAR 2015 DOI: /bdi
10 Bipolar Recurrence Vázquez, G.H., et al., European Neuropsychopharmacology (2015), org/ /j.euroneuro
11 Bipolar Depression: Comorbid Conditions Bipolar Depression Anxiety Disorders Substance Abuse Manic Symptoms
12 Bipolar vs Unipolar Depression Early age of onset More episodes (> 5) Probably Myth More atypical symptoms Hyperphagia and hypersomnia Probably True: More psychosis More frequently postpartum Difficult to differentiate on dep symptoms alone
13 One Symptom Differentiated Bipolar Depression vs MDD Multivariate analysis b OR (95% CI) Psychomotor retardation 1.63 * ( ) Mitchell et al. The British Journal of Psychiatry (2011) 199, doi: /bjp.bp
14 Depressive Symptoms Predominate in BPI N= years of follow up % weeks ill Depressive sx Cycling Mania Judd et al. Arch Gen Psych 59: , 2002
15 Depressive Symptoms Predominate in BPII % weeks ill Depressive sx Cycling N= years of follow up Hypomania Judd et al. Arch Gen Psych 60: , 2003
16 FDA Approved Treatments for Bipolar Depression
17 FDA Approved Olanzapine/Fluoxetine Combination (OFC) Quetiapine Lurasidone (Lamotrigine)
18 OFC for Bipolar I Depression % Response N OFC = 82 Olanzapine = 351 Placebo = 355 P<.001 OFC:placebo p<0.02 olanzapine:placebo Tohen M et al. Arch Gen Psychiatry 60:
19 Olanzapine Fluoxetine Combination Pharmacodynamic profile 5-HT 2c antagonist that increases DA and NE Prefrontal cortex and hypothalamus Histaminergic antagonist decreases energy expenditure Muscarinic 3R antagonist decreases insulin secretion Metabolized through CYP450 3A4 Olanzapine t½ 30 hours Fluoxetine/NorFluox 2 to 4 days S. Koch et al. Neuropharmacology 46 (2004) ; He et al. Psychoneuroendocrinology (2014) 42, ; Weston-Green et al. CNS Drugs (2013) 27:
20 OFC for Bipolar I Depression Adjunctive with lithium or valproate Side effects Weight gain, dry mouth, asthenia, diarrhea Metabolic syndrome Discontinuation rates (8 week study) 61.5% placebo; 51.6% olanzapine, 36% OFC
21 Quetiapine for Bipolar I or II Depression % Response N Quetiapine 300 mg = 172 Quetiapine 600 mg = 170 Placebo = 169 P<0.001 active:placebo Calabrese et al., Am J Psychiatry Jul;162(7):
22 Quetiapine Pharmacodynamic profile D2 antagonist 5-HT 2a antagonist Alpha 2c adrenergic agonist 5-HT 1A partial agonist Alpha 1 adrenergic antagonist Histaminergic antagonist Muscarinic antagonist Metabolized through CYP450 3A4 t½ 6 hours
23 Quetiapine Monotherapy or adjunctive Side effects Dry mouth, sedation, somnolence, dizziness, fatigue, constipation, headache, nausea Metabolic syndrome Discontinuation rates (8 week study) Placebo 40.1%; QTP 300 mg 33.1%; QTP 600 mg 45.5% Calabrese et al. Am J Psychiatry 2005; 162:
24 Lurasidone for Bipolar I Depression % Response N Lurasidone 20-60mg = 166 Lurasidone mg = 169 Placebo = 170 P<0.001 active:placebo Lobel A, et al. Presented at 64 th Institute of Psychiatric Services Meeting PS1-06.
25 Lurasidone Pharmacodynamic profile D2 antagonist 5-HT 2a, 5-HT7 antagonist Alpha 2c adrenergic agonist 5-HT 1A partial agonist Alpha 2a adrenergic antagonist No affinity for histaminergic or muscarinic receptors Metabolized through CYP450 3A4 t½ 18 hours; steady state in 7 days
26 Lurasidone for Bipolar I Depression Monotherapy Adjunctive with lithium or valproate Side effects akathisia, extrapyramidal symptoms, somnolence, nausea, vomiting, diarrhea, and anxiety Discontinuation rates (6 week studies) 4.8% placebo; 5.8% lurasidone Take with food (350 cal)
27 Comparative Weight Gain (Schizophrenia) Leucht et al. Lancet 2013; 382:
28 Comparative Sedation Leucht et al. Lancet 2013; 382:
29 Lamotrigine Approved for the prevention of mood episodes Not approved for acute treatment of bipolar depression 5 trials 4 could not distinguish LTG from placebo Modest effect size in meta-analysis But clinicians use LTG anyway Geddes J R et al. BJP 2009;194:4-9
30 Lamotrigine Pharmacodynamic profile Desensitization of the terminal 5HT 1B autoreceptors Increase 5HT1a activity Inhibit glutamate release decreased glutamate transmission in the dentate gyrus No affinity for histaminergic or muscarinic receptors Metabolized through CYP450 3A4 (increased with VPA) Shim et al. J Pharmacol Exp Ther 347: , November 2013
31 Lamotrigine Side effects Benign rash 8.3% and 6.4% in lamotrigine- and placebo-treated patients Stevens Johnson Syndrome (toxic epidermal necrosis) 0% with lamotrigine, 0.1% (N = 1) with placebo, and 0% with comparators. In the open-label setting, the overall rate of rash for lamotrigine was 13.1% and of serious rash, 0.1% Decrease risk with slow titration Headache, nausea, dizziness, infection Calabrese et al. J Clin Psychiatry 2002;63(11): Bowden et al. Drug Safety 2004; 27 (3):
32 Lamotrigine compared with placebo: meta-analysis of randomised trials by The Royal College of Psychiatrists Geddes J R et al. BJP 2009;194:4-9
33 Randomised trials comparing lamotrigine with placebo stratified by baseline severity of Hamilton Rating Scale for Depression (17-item version) by The Royal College of Psychiatrists Geddes J R et al. BJP 2009;194:4-9
34 Lamotrigine plus Lithium 30 MADRS Lamotrigine Placebo * ** * p=0.031 ** p= Van der Loos et al. J Clin Psych 2009 Baseline Week 2 Week 4 Week 6 Week 8
35 Olanzapine vs. Lamotrigine Pan et al. BMC Psychiatry 2014, 14:145
36 Lamotrigine vs Lithium Kessing et al. J Psychopharmacol : 644
37 Mechanisms of Action Differs Effective from Non- Effective Treatments for BP Depression Receptor Action Result Alpha 1 Antagonist Increase NE D1 Antagonist Decrease DA H1 Antagonist Decrease Histamine 5HT2A Antagonist Increase 5HT Muscarinic Antagonist Decrease Acetylcholine D2 Antagonist Mixed effects D3 Antagonist Increase DA NE Reuptake Inhibition Increase NE 5HT1A Agonism Increase 5HT Fountoulakas et al. Journal of Affective Disorders 138 (2012)
38 What s the problem with antidepressants? Widespread use. Efficacy? Safety? Long-term harm?
39 What s the problem? Cause Effect Post hoc ergo proctor hoc. After this, therefore, because of this.
40 What is evidence?
41 Meta-analysis of Efficacy of Antidepressants for BP Depression 15 studies 2373 patients No superiority over placebo No increased risk of switch Sidor and MacQueen. J Clin Psychiatry 2011 Feb;72(2): Epub 2010 Oct 5.
42 STEP-BD Randomized Acute Bipolar Depression Study MS plus Antidepressant MS plus placebo 49% 24% 27% 32% 38% 41% Durable Recovery Effectiveness Response Rate At Least Transient Remission >50% SUM-D reduction at week 6 No statistically significant differences, All p>.23 Sachs G et al. N Engl J Med 2007; /NEJMoa064135
43 Treatment Emergent Affective Switch MS plus antidepressant MS plus placebo 17.9% 10.1% 10.7% 10.2% TEAS Subjects with prior TEAS Sachs G et al. N Engl J Med 2007; /NEJMoa064135
44 Practice Based Evidence No benefit with antidepressants for bipolar depression with manic symptoms Note: Observational; Not Randomized Goldberg et al. Am J Psychiatry 2007:164:
45 Antidepressants and Bipolar Depression: Evidence for Efficacy MAOIs - old flawed literature TCAs - increased cycling SSRIs - mixed mostly negative studies SNRIs - increased cycling? Bupropion - no positive studies Lithium, valproate, carbamazepine?
46 Decrease in MADRS EMBOLDEN II BPI = 478 BPII=262 p=.313 Paroxetine vs Placebo McElroy et al. J Clin Psychiatry 2010 Feb;71(2): Epub 2010 Jan 26
47 International Society for Bipolar Disorders Clinical (ISBD) Recommendations for Antidepressant Use in Bipolar Disorders Acute treatment 1. Adjunctive antidepressants may be used for an acute bipolar I or II depressive episode when there is a history of previous positive response to antidepressants. 2. Adjunctive antidepressants should be avoided for an acute bipolar I or II depressive episode with two or more concomitant core manic symptoms in the presence of psychomotor agitation or rapid cycling. Am J Psychiatry Pacchiarotti et al.; AiA:1 14
48 International Society for Bipolar Disorders Clinical (ISBD) Recommendations for Antidepressant Use in Bipolar Disorders Maintenance treatment 3. Maintenance treatment with adjunctive antidepressants may be considered if a patient relapses into a depressive episode after stopping antidepressant therapy. Monotherapy 4. Antidepressant monotherapy should be avoided in bipolar I disorder. 5. Antidepressant monotherapy should be avoided in bipolar I and II depression with two or more concomitant core manic symptoms. Am J Psychiatry Pacchiarotti et al.; AiA:1 14
49 Lithium for bipolar depression?
50 EMBOLDEN I: Li not better than Pbo Decrease in MADRS BPI = 499 BPII=303 p=.123 Lithium vs Placebo McElroy et al. J Clin Psychiatry 2010 Feb;71(2): Epub 2010 Jan 26
51 Potential treatments for bipolar depression ECT Ketamine rtms (no randomized studies) Low frequency magnetic stimulation
52 ECT Superior to Pharmacotherapy Response Rates ECT 73.9%, Pharmacotherapy 35.0% Schoeyen et al. Am J Psychiatry 2014;:. doi: /appi.ajp
53 Ketamine for Bipolar Depression Zarate et al. BIOL PSYCHIATRY 2012;71:
54 Low Frequency Magnetic Stim Rohan et al. BIOL PSYCHIATRY 2014;76:
55 Summary Bipolar depression: Basics Frequent problem FDA Approved Treatments OFC QTP Lurasidone LTG (?) Antidepressants and other treatments
Bipolar Depression Update 2016
Bipolar Depression Update 2016 Andrew A. Nierenberg, MD Thomas P. Hackett, MD, Endowed Chair in Psychiatry Director, Bipolar Clinic and Research Program Massachusetts General Hospital Professor of Psychiatry,
More informationDo the Right Thing: Good Clinical Practice for Clinical Research
Do the Right Thing: Good Clinical Practice for Clinical Research Andrew A. Nierenberg, MD Director, Bipolar Clinic and Research Program, Director, Training and Education, MGH Research Institute Massachusetts
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationBipolar Depression: Engaging the Patient. Mark Frye, MD Mayo Clinic Rochester, MN
Bipolar Depression: Engaging the Patient Mark Frye, MD Mayo Clinic Rochester, MN Mark Frye, MD Disclosures Research/Grants: AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationTreatment of Bipolar disorder
8/6/215 Treatment of Bipolar disorder Pichai Ittasakul, M.D. Department of Psychiatry, Ramathibodi Hospital, Mahidol University Bipolar disorder Manic-depressive Illness. is characterized by the occurrence
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationPsychiatry Clinical Reviews Treating Bipolar Depression
Mayo School of Continuous Professional Development Psychiatry Clinical Reviews Treating Bipolar Depression Mark A. Frye, MD October 6-8, 2016 Intercontinental Chicago Magnificent Mile Chicago, IL 2015
More informationImproving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
More informationObjectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System
Conflicts of Interest I have no conflicts to disclose. 2014 Updates to the Updates in Pharmacotherapy Webinar Psychiatry Updates for Pharmacotherapy Specialists Jacintha S. Cauffield, Pharm.D., BCPS Associate
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationManagement of Bipolar Depression
Management of Bipolar Depression Haresh M. Tharwani, M.D. Associate Clinical Professor Medical Director-DRH & Duke Psychiatry Specialty Clinic of Cary, N.C. Bipolar Disorders (Manic-Depressive illness)
More informationClinical Use of Ketamine in Psychiatry
Clinical Use of Ketamine in Psychiatry C. Sophia Albott, MD, MA Assistant Professor Department of Psychiatry and Behavioral Sciences University of Minnesota Medical School November 17, 2018 Disclosure
More informationAdvancing our Thinking About Partially Responsive MDD and TRD. Thomas Laughren, M.D. Laughren Psychopharm Consulting, LLC
Advancing our Thinking About Partially Responsive MDD and TRD Thomas Laughren, M.D. Laughren Psychopharm Consulting, LLC 1 Current & Past Consulting Relationships Part time employee of MGH CTNI Consultant
More informationDesktop Delivery Cover Sheet
InterLibrary Loan Article Delivery Service http://www.library.uthscsa.edu/illiad ariel-ill@uthscsa.edu Briscoe Library 7703 Floyd Curl Drive San Antonio, TX 78229 (210) 567-2460 (210) 567-2463 (fax) Desktop
More informationCNS SPECTRUMS. CME Review Article. Treatment of Bipolar Depression: Making Sensible Decisions
CNS SPECTRUMS CME Review Article Treatment of Bipolar Depression: Making Sensible Decisions This activity is sponsored by the Neuroscience Education Institute CME Information Accreditation and Credit Designation
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationPDF created with pdffactory Pro trial version
با ی د ر ا ر وه روا ز ش ی دا ه ع وم ش ی ا ان Treatment Challenges in BD Major depressive episode Mixed states= 20% Rapid cycling= 18% (annually), 31.5% (lifetime) Psychiatric Comorbidity (substance abuse,
More informationBIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD PROFESSOR DEPARTMENT OF PSYCHIATRY UNIVERSITY
More informationWhat s new in the treatment of bipolar disorder?
What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Best Practices in the Management of Bipolar Disorder Robert M. A. Hirschfeld, MD University of Texas Medical Branch Galveston, TX Peter
More informationPharmacotherapy of Bipolar Disorder Roger S. McIntyre, MD, FRCPC
Pharmacotherapy of Bipolar Disorder Roger S. McIntyre, MD, FRCPC Professor of Psychiatry and Pharmacology University of Toronto Head, Mood Disorders Psychopharmacology Unit University Health Network Toronto,
More informationComprehensive Pharmacologic Management of Bipolar Depression Alexander McGirr, MD, MSc 1 David J. Bond, MD, PhD 2,*
Current Treatment Options in Psychiatry (2014) 1:263 277 DOI 10.1007/s40501-014-0017-2 Mood Disorders (AH Young, Section Editor) Comprehensive Pharmacologic Management of Bipolar Depression Alexander McGirr,
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationBipolar Disorder A Focus on Depression
clinical practice Bipolar Disorder A Focus on Depression Mark A. Frye, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies
More informationBeyond the antidepressant label: Neuroscience-based Nomenclature
Beyond the antidepressant label: Neuroscience-based Nomenclature Pierre Blier, MD, Ph.D Professor, Psychiatry and Cellular & Molecular Medicine University of Ottawa Endowed Chair and Director Mood Disorders
More informationAntidepressant Therapy 2016
Antidepressant Therapy 2016 Michael E. Thase, MD University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh Medical Center thase@mail.med.upenn.edu
More informationBipolar Disorders Expert Column Series Rapid-Cycling Bipolar Disorder: Emerging Treatments and Enduring Controversies
To Print: Click your browser's PRINT button. Bipolar Disorders Expert Column Series Rapid-Cycling Bipolar Disorder: Emerging Treatments and Enduring Controversies Joseph F. Goldberg, MD; Jinger Hoop, MD
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationA BS TR AC T. n engl j med 356;17 april 26,
The new england journal of medicine established in 1812 april 26, 2007 vol. 356 no. 17 Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression Gary S. Sachs, M.D., Andrew A. Nierenberg,
More informationAntipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD
Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra North Shore - LIJ School of Medicine
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationANXIOUS DEPRESSION. Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University
ANXIOUS DEPRESSION Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University NED H. KALIN, MD Disclosures!! Research/Grants: None!! Speakers Bureau: None!! Consultant: None!!
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationFlorida Best Practice Medication Guidelines Principles of Practice for Adults
http://flmedicaidbh.fmhi.usf.edu Florida Best Practice Medication Guidelines Principles of Practice for Adults 1. Goal of the Guidelines Persistent gaps exist in the quality of mental health care delivered
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationPractical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current Clinical Guidelines
SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR DISORDER Practical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current s Flavio Guzman, MD Editor Psychopharmacology Institute
More informationIt's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum
It's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum Session 4022: American Psychiatric Nurses Association National Conference, Louisville, KY Andrew Penn, RN, MS, NP, CNS Psychiatric
More informationTargets of Psychopharmacological Drug Action
Targets of Psychopharmacological Drug Action (page 33 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry University of California, San Diego School of Medicine Honorary
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationEfficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis
International Journal of Neuropsychopharmacology (2010), 13, 5 14. Copyright f CINP 2009 doi:10.1017/s1461145709990344 Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression:
More informationRegulatory Issues in Targeting Cognitive Impairment in Depression. Thomas Laughren, M.D. Director, Regulatory Affairs MGH CTNI
Regulatory Issues in Targeting Cognitive Impairment in Depression Thomas Laughren, M.D. Director, Regulatory Affairs MGH CTNI 1 Current Financial Relationships Part time employee of MGH CTNI Consultant
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationNOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression)
NOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression) 11 APRIL 2013 Josephine Cucchiaro, PhD Vice President Clinical Operations & Project Management Sunovion Pharmaceuticals
More informationA Critical Review of. Current Guidelines for Bipolar Disorder. R. Hamish McAllister-Williams, MD, PhD, MRCPsych
A Critical Review of Psychobiology Research Group Current Guidelines for Bipolar Disorder R. Hamish McAllister-Williams, MD, PhD, MRCPsych Reader in Clinical Psychopharmacology University of Newcastle
More informationBIPOLAR DISORDERS UPDATE. Anthony Archer, DO
BIPOLAR DISORDERS UPDATE Anthony Archer, DO OBJECTIVES Review the major developments and trends in diagnosis and management of bipolar disorders. Discuss and promote the role of the primary care physician
More informationBipolar Disorders. Disclosure Statement. I have no financial disclosures or conflicts of interest
Bipolar Disorders Ahsan Naseem, MD Diplomate American Board of Psychiatry and Neurology Adult and Geriatric Psychiatry Medical Director Bryan Heartland Psychiatry Bryan Physician Network Partner Cheney
More informationBrief Report. Published by John Wiley & Sons Ltd.
Bipolar Disorders 2015: 17: 212 223 Brief Report 2014 John Wiley & Sons A/S Published by John Wiley & Sons Ltd. BIPOLAR DISORDERS Medical burden in bipolar disorder: findings from the Clinical and Health
More informationLithium in bipolar disorders.
Lithium in bipolar disorders. S. Mehdi Samimi Ardestani M.D. Department of Psychiatry, Shahid Beheshti University of Medical Science, Behavioral science research center Iranian psychiatric association,
More informationN e w s R e l e a s e
Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 N e w s R e l e a s e Contact: Patrick Gaffey Senior Director, Corporate Communications Sunovion Pharmaceuticals
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationOlanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
International Journal of Neuropsychopharmacology (2009), 12, 773 782. Copyright f 2008 CINP doi:10.1017/s1461145708009735 Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar
More informationLinda Carpenter, M.D.
Stress, Depression and Physical Health Linda Carpenter, M.D. Associate Professor of Psychiatry and Human Behavior and Medicine Alpert Medical School of Brown University Chief, Butler Hospital Mood Disorders
More informationCognitive Impairment in Major Depressive Disorder as a Target for Drug Development
Cognitive Impairment in Major Depressive Disorder as a Target for Drug Development Maurizio Fava, MD Director Clinical Research Program Executive Vice Chair Department of Psychiatry Executive Director
More informationSolving Clinical Challenges in Bipolar Disorder
Overview Bipolar Disorder Solving Clinical Challenges Solving Clinical Challenges in Bipolar Disorder Terence A. Ketter, MD Professor Emeritus Department of Psychiatry and Behavioral Sciences Stanford
More informationRegulatory Challenges in Targeting Cognitive Impairment in Depression. Thomas Laughren, M.D. Director, Regulatory Affairs MGH CTNI
Regulatory Challenges in Targeting Cognitive Impairment in Depression Thomas Laughren, M.D. Director, Regulatory Affairs MGH CTNI 1 Current & Past Consulting Relationships Part time employee of MGH CTNI
More informationPediatrics Grand Rounds 5 March University of Texas Health Science Center at San Antonio I-1
Diagnosis and Treatment of Depression in Children and Adolescents Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The Disclosures
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationAge / Sex: Presenting Problem:
William E. Bunney, Jr., MD, and Ned H. Kalin, MD Chart Review: Anxious Depression PATIENT INFO 17 / Female Age / Sex: Presenting Problem: DA is 17 y/o women who presented with intermittent symptoms of
More informationComparison of the Usefulness of Lithium and Valproate
Review Article CNPT4(2013) 1-5 Comparison of the Usefulness of Lithium and Valproate, M.D., Ph.D. Department of Neuropsychiatry, Oita University Faculty of Medicine ABSTRACT This review shows that lithium
More informationWhat s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry
What s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry New Depression Screening Guidelines US Preventive Services Task Force (USPSTF) updated its 2009 recommendations
More informationElan, GlaxoSmithKline, Janssen, Johnson & Johnson, Lilly Research, Parke Davis, Robert Wood Johnson and Smith Kline Beecham
2 Kenneth Altshuler MD Center Dallas Janssen 3 4 Lori Altshuler MD UCLA Abbott Western Psychiatric Institute Boris Birmaher MD Pittsburg, PA Forest Eli Lilly, Forest, Janssen, AstraZeneca,, GlaxoSmithKline,
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More informationPoor quality of life and functioning in bipolar disorder
DOI 10.1186/s40345-017-0078-4 RESEARCH Open Access Poor quality of life and functioning in bipolar disorder Louisa G. Sylvia 1,2*, Rebecca E. Montana 1, Thilo Deckersbach 1,2, Michael E. Thase 3, Maurcio
More informationEmerging Treatments in Bipolar Disorder: Fall 2015 Update
Emerging Treatments in Bipolar Disorder: Fall 2015 Update Roy H. Perlis, MD MSc Center for Experimental Drugs and Diagnostics Massachusetts General Hospital Harvard Medical School rperlis@partners.org
More informationPractice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,
Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationOverview Treatment-Resistant Bipolar Disorder. Management of Bipolar Disorder When First-Line Interventions Fail Practical Tips
Overview Management of Bipolar Disorder When Interventions Fail Practical Tips Terence A. Ketter, MD Professor of Psychiatry and Behavioral Sciences Stanford University School of Medicine Stanford, California
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationTreatment Resistant Depression: A Systematic Approach to Management
Treatment Resistant Depression: A Systematic Approach to Management Michael E. Thase, M.D. University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationPRODUCT INFORMATION TEVATIAPINE XR (quetiapine fumarate)
PRODUCT INFORMATION TEVATIAPINE XR (quetiapine fumarate) NAME OF THE MEDICINE Active ingredient: Quetiapine fumarate Chemical Name: Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin-1-yl] ethoxy)
More informationPlease see Brief Summary of full Prescribing Information, including Boxed Warning, on page S17.
SUPPLEMENT TO Available at CLINICIANREVIEWS.COM A F R O N T L I N E M E D I C A L C O M M U N I C AT I O N S P U B L I C AT I O N April 2015 Dezra L. Kenney, PMHCNS-BC, CADAC Danielle L. Kamine, MS, ARNP,
More informationWhat's New in the World of Antipsychotics?
Handout for the Neuroscience Education Institute (NEI) online activity: What's New in the World of Antipsychotics? (page 7 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationSponsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy
The Future of Antipsychotic Therapy (page 7 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry University of California, San Diego School of Medicine Honorary Visiting Senior
More informationUniversity of Groningen. Lamotrigine in bipolar depression Loos, Marcus Lambertus Maria van der
University of Groningen Lamotrigine in bipolar depression Loos, Marcus Lambertus Maria van der IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationDifferentiating Unipolar vs Bipolar Depression in Children
Differentiating Unipolar vs Bipolar Depression in Children Mai Uchida, M.D. Director, Center for Early Identification and Prevention of Pediatric Depression Massachusetts General Hospital Assistant Professor
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationStahl s Illustrated. Antidepressants. Stephen M. Stahl. University of California at San Diego. Nancy Muntner. Illustrations. Angela Felker.
Antidepressants Stephen M. Stahl University of California at San Diego Nancy Muntner Illustrations Angela Felker Editor ii PREFACE These books are designed to be fun. All concepts are illustrated by full-color
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationImproving Diagnosis and Symptoms in Patients With Bipolar Depression: Contemporary Strategies Discussion 1
Discussion 1 The following is a transcript from a Web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by an educational
More informationABSTRACT ORIGINAL RESEARCH. Roger S. McIntyre. Emmanuelle Weiller
Adv Ther (2015) 32:429 444 DOI 10.1007/s12325-015-0207-3 ORIGINAL RESEARCH Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response
More informationPharmacotherapy of Bipolar Depression: An Update
Pharmacotherapy of Bipolar Depression: An Update Michael E. Thase, MD Corresponding author Michael E. Thase, MD University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O
More information) and serotonin Type 2 (5-HT 2A
Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the
More informationCNS SPECTRUMS. CME Review Article. A review of FDA-approved treatment options in bipolar depression
CNS SPECTRUMS CME Review Article A review of FDA-approved treatment options in bipolar depression This activity is sponsored by the Neuroscience Education Institute CME Information Accreditation and credit
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 2 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationBipolar Disorder Demystified. Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry
Bipolar Disorder Demystified Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry Underdiagnoses of Depression In Primary Care 2005 Study of 650 primary care patients on antidepressants
More informationForty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
Adelaide Robb, MD Associate Professor Psychiatry and Pediatrics Source Advisory Board Disclosure Speaker s Bureau Bristol Myers Squibb Yes Yes Yes Epocrates Research Contract Royalties Yes Stock Janssen
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More information